Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A guanine derivative with an acyclic side chain, 2-hydroxyethoxymethyl, at position 9 has potent antiviral activity [dose for 50% inhibition (ED 50 ) = 0.1 μM] against herpes simplex virus type 1. This acyclic nucleoside analog, termed acycloguanosine, is converted to a monophosphate by a virus-specified pyrimidine deoxynucleoside (thymidine) kinase and is subsequently converted to acycloguanosine di- and triphosphates. In the uninfected host cell (Vero) these phosphorylations of acycloguanosine occur to a very limited extent. Acycloguanosine triphosphate inhibits herpes simplex virus DNA polymerase (DNA nucleotidyltransferase) 10-30 times more effectively than cellular (HeLa S3) DNA polymerase. These factors contribute to the drug's selectivity; inhibition of growth of the host cell requires a 3000-fold greater concentration of drug than does the inhibition of viral multiplication. There is, moreover, the strong possibility of chain termination of the viral DNA by incorporation of acycloguanosine. The identity of the kinase that phosphorylates acycloguanosine was determined after separation of the cellular and virus-specified thymidine kinase activities by affinity chromatography, by reversal studies with thymidine, and by the lack of monophosphate formation in a temperature-sensitive, thymidine kinase-deficient mutant of the KOS strain of herpes simplex virus type 1 (tsA1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DISC ELECTROPHORESIS – II METHOD AND APPLICATION TO HUMAN SERUM PROTEINS*
Davis, B. J. (1964) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1964.tb14213.x · Cited by 18,892
DISC ELECTROPHORESIS IN POLYACRYLAMIDE GELS: EXTENSION TO NEW CONDITIONS OF p H AND BUFFER
Williams, D. E., & Reisfeld, R. A. (1964) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1964.tb14210.x · Cited by 651
ENZYMATIC PHOSPHORYLATION OF ADENOSINE AND 2,6-DIAMINOPURINE RIBOSIDE
Kornberg, A., & Pricer, W. E. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50904-2 · Cited by 492
Induction of Both Thymidine and Deoxycytidine Kinase Activity by Herpes Viruses
Jamieson, A. T., Gentry, G. A., & Subak-Sharpe, J. H. (1974) · Journal of General Virology · doi:10.1099/0022-1317-24-3-465 · Cited by 288
Characterization of Herpes Simplex Virus-induced Deoxyribonucleic Acid Polymerase
Weissbach, A., Hong, S. L., Aucker, J., & Müller, R. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43443-1 · Cited by 203
Biochemical Studies on the Herpes Simplex Virus-specified Deoxypyrimidine Kinase Activity
Jamieson, A. T., & Subak-Sharpe, J. H. (1974) · Journal of General Virology · doi:10.1099/0022-1317-24-3-481 · Cited by 177
Human cytomegalovirus. III. Virus-induced DNA polymerase
Huang, E. S. (1975) · Journal of Virology · doi:10.1128/jvi.16.2.298-310.1975 · Cited by 150
Ribonucleotide Reductase Activity of Synchronized KB Cells Infected with Herpes Simplex Virus
Cohen, G. H. (1972) · Journal of Virology · doi:10.1128/jvi.9.3.408-418.1972 · Cited by 134
Novel substrate of adenosine deaminase
Schaeffer, H. J., Gurwara, S., Vince, R., & Bittner, S. (1971) · Journal of Medicinal Chemistry · doi:10.1021/jm00286a024 · Cited by 101
Self-citationCheng, Y., Domin, B. A., Sharma, R. A., & BOBEK, M. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.10.1.119 · Cited by 100
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Herpes simplex virus infections
Whitley, R. J., & Roizman, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04638-9 · Cited by 1,366
9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group
Schaeffer, H. J., Beauchamp, L., de Miranda, P., Elion, G. B., Bauer, D. J., & Collins, P. (1978) · Nature · doi:10.1038/272583a0 · Cited by 1,140
Self-citationVidarabine versus Acyclovir Therapy in Herpes Simplex Encephalitis
Whitley, R. J., Alford, C. A., Hirsch, M. S., Schooley, R. T., Luby, J. P., Aoki, F. Y., Hanley, D., Nahmias, A. J., Soong, S.-J., & The NIAID Collaborative Antiviral Study Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198601163140303 · Cited by 896
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Clercq, E. D., & Holý, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1877 · Cited by 688
The purine path to chemotherapy
Elion, G. B. (1989) · Science · doi:10.1126/science.2649979 · Cited by 687
Self-citationACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS
Sköldenberg, B., Alestig, K., Burman, L., Forkman, A., Lövgren, K., Norrby, R., Stiernstedt, G., Forsgren, M., Bergström, T., Dahlqvist, E., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92623-0 · Cited by 610
Comparative Efficacy of Antiherpes Drugs against Different Strains of Herpes Simplex Virus
De Clercq, E., Descamps, J., Verhelst, G., Walker, R. T., Jones, A. S., Torrence, P. F., & Shugar, D. (1980) · Journal of Infectious Diseases · doi:10.1093/infdis/141.5.563 · Cited by 604
Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W., & Lietman, P. S. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107093050202 · Cited by 591
Fyfe, J. A., Keller, P. M., Furman, P. A., Miller, R. L., & Elion, G. B. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34236-9 · Cited by 562
Self-citationSeley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., & Sutton, D. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.114-128.2003 · Cited by 504
Antiviral drugs for cytomegalovirus diseases
Biron, K. K. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.002 · Cited by 468
(1986) · The Lancet · doi:10.1016/s0140-6736(86)90889-5 · Cited by 465
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Odumade, O. A., Hogquist, K. A., & Balfour, H. H. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00044-10 · Cited by 458
Zhong, W., Wang, H., Herndier, B., & Ganem, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6641 · Cited by 456
Wood, A. J. J., Whitley, R. J., & Gnann, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209103271108 · Cited by 410
Wald, A., Corey, L., Cone, R., Hobson, A., Davis, G., & Zeh, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119237 · Cited by 388
A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection
Whitley, R., Arvin, A., Prober, C., Burchett, S., Corey, L., Powell, D., Plotkin, S., Starr, S., Alford, C., Connor, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240703 · Cited by 388
Sustained-and Controlled-Release Drug-Delivery Systems
Robinson, J., & Jantzen, G. (2002) · Drugs and the Pharmaceutical Sciences · doi:10.1201/9780824744694.ch15 · Cited by 385
Mechanism of action and selectivity of acyclovir
Elion, G. B. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90055-9 · Cited by 370
Self-citationCoen, D. M., Kosz-Vnenchak, M., Jacobson, J. G., Leib, D. A., Bogard, C. L., Schaffer, P. A., Tyler, K. L., & Knipe, D. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.12.4736 · Cited by 362
Microalgae as Sources of High Added-Value Compounds—A Brief Review of Recent Work
Guedes, A. C., Amaro, H. M., & Malcata, F. X. (2011) · Biotechnology Progress · doi:10.1002/btpr.575 · Cited by 348
“extracts inactivates the initial viral function right after Stage I.(59,60) Sulphated exopolysaccharides from marine microalgae have been claimed to interfere with Stage I of some enveloped viruses;(61) they offer unique advantages, due to their antiviral spectrum against, e.”
BackgroundResistance to Antiviral Drugs of Herpes Simplex Virus Isolated from a Patient Treated with Acyclovir
Crumpacker, C. S., Schnipper, L. E., Marlowe, S. I., Kowalsky, P. N., Hershey, B. J., & Levin, M. J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198202113060606 · Cited by 345
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
De Clercq, E., & Field, H. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 336
Wald, A., Huang, M., Carrell, D., Selke, S., & Corey, L. (2003) · The Journal of Infectious Diseases · doi:10.1086/379043 · Cited by 330
WADE, J. C., NEWTON, B., McLAREN, C., FLOURNOY, N., KEENEY, R. E., & MEYERS, J. D. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-3-265 · Cited by 329
Furman, P. A., St Clair, M. H., Fyfe, J. A., Rideout, J. L., Keller, P. M., & Elion, G. B. (1979) · Journal of Virology · doi:10.1128/jvi.32.1.72-77.1979 · Cited by 328
Self-citationBryson, Y. J., Dillon, M., Lovett, M., Acuna, G., Taylor, S., Cherry, J. D., Johnson, B. L., Wiesmeier, E., Growdon, W., Creagh-Kirk, T., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304213081602 · Cited by 317
Whitley, R. J., & Lakeman, F. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.2.414 · Cited by 309
Balfour, H. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401608 · Cited by 285
Nucleoside Analogues as Chemotherapeutic Agents: A Review
Périgaud, C., Gosselin, G., & Imbach, J. L. (1992) · Nucleosides and Nucleotides · doi:10.1080/07328319208021748 · Cited by 277
Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase.
Miller, W. H., & Miller, R. L. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)79686-9 · Cited by 267
Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine
Smee, D. F., Martin, J. C., Verheyden, J. P., & Matthews, T. R. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.5.676 · Cited by 265
Meyers, J. D., Wade, J. C., Mitchell, C. D., Saral, R., Lietman, P. S., Durack, D. T., Levin, M. J., Segreti, A. C., & Balfour, H. H. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90097-3 · Cited by 261
Antiviral Drug Resistance: Mechanisms and Clinical Implications
Strasfeld, L., & Chou, S. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.001 · Cited by 254
Cheng, Y. C., Huang, E. S., Lin, J. C., Mar, E. C., Pagano, J. S., Dutschman, G. E., & Grill, S. P. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.9.2767 · Cited by 253
Marine compounds and their antiviral activities
Yasuhara-Bell, J., & Lu, Y. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.03.009 · Cited by 245
“Other examples of products of semi-synthetic odifications of the arabinosyl nucleosides are Ara-C (cytarabine) Privat de Garilhe and de Rudder, 1964), acyclovir (Elion et al., 1977) nd azidothymidine (zidovudine) (Horwitz et al., 1964), which are, owadays, in clinical use (Table 1).”
Biron, K. K., Stanat, S. C., Sorrell, J. B., Fyfe, J. A., Keller, P. M., Lambe, C. U., & Nelson, D. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.8.2473 · Cited by 236
Self-citationAltered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.
Furman, P. A., St Clair, M. H., & Spector, T. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42739-6 · Cited by 197
Self-citationWade, J. C., McLaren, C., & Meyers, J. D. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/148.6.1077 · Cited by 180
“Before it is active as an antiviral agent, acyclovir must be monophosphorylated by virus-specified thymidine kinase and then by cellular kinases, with triphosphorylated acyclovir acting as an inhibitor of viral DNA polymerase [4].”
BackgroundHelicase–Primase Inhibitor Pritelivir for HSV-2 Infection
Wald, A., Corey, L., Timmler, B., Magaret, A., Warren, T., Tyring, S., Johnston, C., Kriesel, J., Fife, K., Galitz, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1301150 · Cited by 176
“Serious adverse events 0 0 1 (3)* 0 0 1 (1)”
Mathur, V., Burai, R., Vest, R. T., Bonanno, L. N., Lehallier, B., Zardeneta, M. E., Mistry, K. N., Do, D., Marsh, S. E., Abud, E. M., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.032 · Cited by 175
Acyclovir in the Treatment of Herpes Viruses – A Review
Kłysik, K., Pietraszek, A., Karewicz, A., & Nowakowska, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867325666180309105519 · Cited by 169
The purine path to chemotherapy
Elion, G. B. (1989) · Bioscience Reports · doi:10.1007/bf01119794 · Cited by 166
Self-citationKatritzky, A. R., Hall, C. D., El-Gendy, B. E.-D. M., & Draghici, B. (2010) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-010-9359-z · Cited by 161
Long, H. M., Leese, A. M., Chagoury, O. L., Connerty, S. R., Quarcoopome, J., Quinn, L. L., Shannon-Lowe, C., & Rickinson, A. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100590 · Cited by 79
“However, that presentation was independent of virion production and release, because ACV treatment of semipermissive LCLs to inhibit late cycle entry (34) did not reduce IE or E Ag presentation.”
BackgroundGreen analytical methodologies for the discovery of bioactive compounds from marine sources
Duarte, K., Justino, C. I. L., Pereira, R., Freitas, A. C., Gomes, A. M., Duarte, A. C., & Rocha-Santos, T. A. P. (2014) · Trends in Environmental Analytical Chemistry · doi:10.1016/j.teac.2014.11.001 · Cited by 21
Metadata
- Authors
- Elion, G. B., Furman, P. A., Fyfe, J. A., Miranda, P. D., Beauchamp, L., & Schaeffer, H. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1977-12
- Volume
- 74
- Issue
- 12
- Pages
- 5716-5720
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2045360603
- Cited by
- 1,591
- References
- 13
- FWCI
- 39.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.